Precautions when using pemetinib

Pemetinib is a targeted therapy drug for patients with cholangiocarcinoma with FGFR2 gene mutation. It prevents the proliferation and spread of cancer cells by inhibiting the FGFR2 signaling pathway. However, as a powerful drug, pemetinib requires patients and doctors to pay attention to multiple aspects during its use to ensure the safety and effectiveness of the treatment.

Before taking pemetinib, patients should be honest with their doctor about their health, especially if they have elevated phosphate levels in the blood, vision or eye problems, severely reduced liver function, severely reduced kidney function, or if cancer cells have spread to the brain or spinal cord. These conditions may affect the efficacy of pemetinib or increase the risk of adverse reactions.

For vision problems, pemetinib may cause eye problems such as dry eye and retinopathy. Therefore, before starting treatment, the doctor will arrange for a comprehensive eye examination by an eye specialist, and re-examination every 2 months for the first 6 months of treatment, and every 3 months thereafter, or as soon as any visual symptoms (such as flashes of light, visual disturbances, or black spots) occur. Patients should also pay close attention to changes in vision in daily life and inform their doctor immediately if any abnormalities are found.

Additionally, to relieve eye dryness that may be caused by pemetinib, patients can use lubricating or moisturizing eye drops or gels as needed.

In short, although pemetinib provides new treatment hope for patients with cholangiocarcinoma, its use requires close cooperation between patients and doctors to jointly monitor and manage possible side effects. Patients should take medication accurately according to the doctor's instructions, and pay close attention to their physical condition and adverse reactions so that they can adjust their treatment plan in a timely manner. At the same time, regular eye examinations and liver function monitoring are also important links to ensure the safe and effective use of pemetinib.

xa0

Reference link: https://www.gov.uk/government/publications/pemigatinib-in-the-treatment-of-cholangioarcinoma/pemigatinibtreatment-protocol-information-for-patients